<DOC>
<DOCNO>EP-0657440</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Oxazolidine-2-one derivatives as MAO inhibitors
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31422	C07D26324	C07D41314	C07D41300	A61P2522	A61K31425	C07D41304	A61K31421	A61P2520	A61P2524	A61K3142	A61K3144	A61K31425	A61P2526	A61K31421	C07D41310	A61K3142	A61K31445	A61P2500	A61P2500	A61K31422	C07D26300	A61P2528	A61K3144	A61K31445	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	C07D	C07D	C07D	A61P	A61K	C07D	A61K	A61P	A61P	A61K	A61K	A61K	A61P	A61K	C07D	A61K	A61K	A61P	A61P	A61K	C07D	A61P	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	C07D263	C07D413	C07D413	A61P25	A61K31	C07D413	A61K31	A61P25	A61P25	A61K31	A61K31	A61K31	A61P25	A61K31	C07D413	A61K31	A61K31	A61P25	A61P25	A61K31	C07D263	A61P25	A61K31	A61K31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to oxazolidin-2-one derivatives of the formula   
<
IMAGE
>
  wherein     R is hydrogen or lower alkyl; X is cycloalkenyl; bicyclo[2.2.1]hept-2-yl, opt. substituted by phenyl-2-oxo-5-methoxymethyloxazolidinyl; bicyclo[2.2.1]
hept-5-en-2-yl; adamantyl; or cycloalkyl or piperidine, optionally mono- or polysubstituted by halogen, amino, lower alkyl, nitrile, an oxo group, hydroxyimino, ethylenedioxy  or by -OR
<
1
>
, wherein R
<
1
>
 is -CH(C6H5)2, -(CH2)nC6H5, lower alkyl, hydrogen, - (CH2)nNHCOCH3, -(CH2)nNH2, -(CH2)nSOCH3, -(CH2)nCN, -(CH2) nSCH3, -(CH2)nSO2CH3, -CO-lower alkyl, -COC6H5, opt. substituted by an oxazolidinyl group:  or by =CR
<
2
>
R
<
3
>
, wherein     R
<
2
>
 is hydrogen or lower alkyl;   R
<
3
>
 is hydrogen, nitrile, lower alkyl, phenyl or COO-lower alkyl;  or by -(CH2)nR
<
4
>
, wherein  R
<
4
>
 is nitrile, amino, -NHCOCH3, -COC6H5Hal, phenyl or hydroxyl;  or by -COR
<
5
>
, wherein R
<
5
>
 is lower alkyl, -CH=CH-C6H5, -C6H5CF3, -O-C(CH3)3 or -O-lower alkyl; or by -NR
<
6
>
R
<
7
>
, wherein     R
<
6
>
 is hydrogen or -COCH3;   R
<
7
>
 is -COCH3, benzyl or -(CH2)nNHCOC6H4Hal;     n is 1-3;   Y
<
1
>
 is -CH= or -N=;   Y
<
2
>
 is -CH=, -C(OH)=, -C(NO2)=, -C(NH2)=, -C(Hal)= or -N= and pharmaceutically acceptable salts of basic compounds of the formula I with acids. These novel compounds and their pharmaceutically acceptable salts can be used for the prevention or control of depressive states, panic and anxiety states, cognitive disorders and neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
Compounds of the general formula 

 
wherein 


R
signifies C
1
―C
4
-alkyl; 
X
signifies C
3
―C
7
-cycloalkenyl; bicyclo[2.2.1]hept-2-yl, 

optionally substituted by phenyl-2-oxo-5-methoxymethyloxazolidinyl; 
bicyclo[2.2.1]
-hept-5-en-2-yl; adamantyl; or C
3
―C
7
-cycloalkyl 
or piperidinyl, optionally mono- or multiply-substituted by 

halogen, amino, C
1
―C
4
-alkyl, nitrilo, an oxo group, hydroxyimino, 
ethylenedioxy 
 
or by-OR
1
, in which 

R
1
signifies -CH(C
6
H
5
)
2
, -(CH
2
)
n
C
6
H
5
, C
1
―C
4
-alkyl, 
hydrogen, -(CH
2
)
n
NHCOCH
3
, -(CH
2
)
n
NH
2
, -(CH
2
)
n
CN,-(CH
2
)
n
SCH
3
, 
-(CH
2
)
n
SO
2
CH
3
, -CO-C
1
―C
4
-alkyl, -COC
6
H
5
, 
optionally substituted by an oxazolidinyl group; 
 
or by =CR
2
R
3
, in which 

R
2
signifies hydrogen or C
1
―C
4
-alkyl; 
R
3
signifies hydrogen, nitrilo, C
1
―C
4
-alkyl, phenyl or 
COO-C
1
―C
4
-alkyl; 
 
or by -(CH
2
)
n
R
4
, in which 

R
4
signifies nitrilo, amino, -NHCOCH
3
, -COC
6
H
5
Hal, 
phenyl or hydroxy; 
 
or by -COR
5
, in which 

R
5
signifies C
1
―C
4
-alkyl, -CH=CH-C
6
H
5
, -C
6
H
5
CF
3
, 
-O-C(CH
3
)
3
 or OC
1
―C
4
-alkyl; 
 
or by -NR
6
R
7
, in which 

R
6
signifies hydrogen or -COCH
3
; 
R
7
signifies -COCH
3
, benzyl or (CH
2
)
n
NHCOC
6
H
4
Hal; 
n
signifies 1-3; 
Y
1
signifies -CH= and  
 
Y
2
signifies -CH=, -C(OH)=, -C(NO
2
)=, -C(NH
2
)= or -C(Hal)= 
 
as well as pharmaceutically usable salts of basic compounds of formula I with acids. 
Compounds according to claim 1,
 
wherein 


R
signifies C
1
―C
4
-alkyl; 
X
signifies cycloalkyl or piperidinyl, optionally 
substituted by C
1
―C
4
-alkyl, methylene, ethylenedioxy, halogen, 
hydroxy, C
1
―C
4
-alkoxy, by a hydroxyimino or oxo group, by -O-(CH
2
)
2
-R
8
, 
-O-CO-R
9
 or by -NH(CH
2
)
n
NHCOC
6
H
4
R
10
 or 
-CH
2
OH;
 
bicyclo[2.2.1]
hept-2-yl, optionally substituted by 
phenyl-2-oxo-5-methoxymethyl-oxazolidinyl;
 
bicyclo[2.2.1]
hept-5-en-2-yl or 
adamantyl; 
Y
1
 and Y
2
both signify CH groups; 
R
8
signifies -CN or -CH
2
NH
2
; 
R
9
signifies C
1
―C
4
-alkyl, phenyl or phenyl substituted by 
an oxazolidinyl group; 
R
10
signifies halogen and 
n
signifies 1-3. 
Compounds according to claim 2, wherein X signifies cyclohexyl or 
cyclohexyl substituted by an oxo, hydroxy, hydroyimino, methoxy, -O(CH
2
)
2
CN or 
-O(CH
2
)
3
NH
2
 group, R signifies methyl and Y
1
 and Y
2
 signify a CH group. 
The compound (RS)-3-(4-Cyclohexyl-phenyl)-5-methoxymethyl-oxazolidin-2-one.in 
accordance with claim. 1 
The compound (R)-3-(4-Cyclohexylphenyl)-5-methoxymethyl-oxazolidin-2-one 
in accordance with claim 1. 
The compound (R)-3-[4-(4-Oxo-cyclohexyl)-phenyl]-5-methoxymethyl-oxazolidin-2-one 

in accordance with claim 1.  
 
The compound (RS)-3-[trans-4-[4-(5-Methoxymethyl-2-oxo-oxazolidin-3-yl-phenyl]-cyclohexyloxy]
-propionitrile 
in accordance with claim 1. 
The compound (RS)-3-[4-(cis- or trans-4-Hydroxy-4-methyl-cyclohexyl)-phenyl]-5-methoxymethyl-oxazolidin-2-one 

in accordance with claim 1. 
The compound (RS)-3-[4-(cis- or trans-4-Hydroxymethyl-cyclohexyl)-phenyl]-5-methoxymethyl-oxazolidin-2-one 

in accordance with claim 1. 
The compounds 

(RS)-3-[4-(4-oxo-cyclohexyl)-phenyl]-5-methoxymethyl-oxazolidin-2-one; 
(RS)-3-[4-(trans-4-hydroxy-cyclohexyl)-phenyl]-5-methoxymethyl-oxazolidin-2-one; 
(RS)-3-[4-(4-hydroxy-imino-cyclohexyl)-phenyl]-5-methoxymethyl-oxazolidin-2-one; 
(R)-3-[4-(trans-4-hydroxy-cyclohexyl)-phenyl]-5-methoxymethyl-oxazolidin-2-one; 
(RS)-3-[4-(trans-4-methoxy-cyclohexyl)-phenyl]-5-methoxymethyl-oxazolidin-2-one; 
acetic acid (RS)-trans-4-[4-(5-Methoxymethyl-2-oxo-oxazolidin-3-yl)-phenyl]-cyclohexyl 

ester in accordance with claim 1. 
Compounds according to claim 1, wherein X signifies 
bicy
clo[2.2.1]hept-2-yl or bicyclo[2.2.1]
hept-5-en-2-yl. 
Compounds 3-[(1RS,2RS,4SR)-4-Bicyclo[2.2.1]hept-2-yl-phenyl]
-5-methoxymethyl-oxazolidine-2-one 
and 


3-[1RS,2SR,4RS)-4-bicyclo[2.2.1]hept-5-en-2-yl-phenyl]
-5-methoxymethyl-oxazolidin-2-one 
in accordance with claim 1. 
Compounds according to claim 1, wherein X signifies cyclohexyl or 
piperidinyl substituted by -CH
2
CN, -COCH=CH-C
6
H
5
, -O(CH
2
)NH
2
 or 
-OCH
2
CN, R signifies methyl and Y
1
 and Y
2
 signify a CH group. 
Compound (RS)-[trans-4-[4-(5-Methoxymethyl-2-oxo-oxazolidin-3-yl)-phenyl]-cyclohexyl]
-acetonitrile 
in accordance with claim 1.  

 
Compound (R)-[trans-4-[4-(5-Methoxymethyl-2-oxo-oxazolidin-3-yl)-phenyl]-cyclohexyl]
-acetonitrile 
in accordance with claim 1. 
Compound (RS)-4-[4-(5-Methoxymethyl-2-oxo-oxazolidin-3-yl)-phenyl]-1-(1-oxo-3-phenyl-2-(E)-propenyl]
-piperidine 
in accordance with claim 1. 
Compound (RS)-3-[trans-4-[4-(5-Methoxymethyl-2-oxo-oxazolidin-3-yl)-phenyl]-cyclohexyloxy]
ethanamine 
in accordance with claim 1. 
Compound (R)-[trans-4-[4-(5-Methoxymethyl-2-oxo-oxazolidin-3-yl)-phenyl]-cyclohexyloxy]
-acetonitrile 
in accordance with claim 1. 
Compound (RS)-[trans-4-[4-(5-Methoxymethyl-2-oxo-oxazolidin-3-yl)-phenyl]-cyclohexyloxy]
-acetonitrile 
in accordance with claim 1. 
Compound (R)-3-[4-[trans-4-(3-Amino-propoxy)-cyclohexyl]-phenyl]
-5-methoxymethyl-oxazolidin-2-one 
in accordance with claim 1. 
Compounds according to any one of claims 1-20 as well as 
pharmaceutically acceptable salts thereof for use as therapeutically active substances. 
Compounds according to any one of claims 1-20 as well as 
pharmaceutically acceptable salts thereof for use in the control or prevention of panic 

and anxiety states, cognitive disorders and neurodegenerative diseases such as 
Parkinson's disease and Alzheimer's disease. 
A process for the manufacture of compounds according to any one of 
claims 1-20, which process comprises 


a) cyclizing a compound of the formula 

 
wherein X, Y
1
 and Y
2
 have the significances given in claim 1,
 
with diethylcarbonat or phosgen and alkylating, or 
b) reacting a compound of the formula  
 


 
wherein X, Y
1
 and Y
2
 have the significances given in claim 1 and R
3
 signifies 
lower alkyl or benzyl,
 
with a compound of the formula 


 
wherein R
4
 signifies lower alkyl or benzyl,
 
or 
c) treating a compound of the general formula 

 
wherein R, Y
1
 and Y
2
 have the significances given in claim 1 and A signifies a 
leaving group,
 
with a reactive agent yielding the substituent X, or 
d) catalytically hydrogenating a compound of the formula 

 
wherein X' signifies a (C
5
-C
7
)-cycloalkenyl residue, which
 
can be substituted as described in formula I for cycloalkyl or piperidinyl, and 

Y
1
, Y
2
 and R have the significances given in formula I,  
 

to the corresponding saturated cycloalkyl compound, or 
e) hydrolyzing a compound of formula I in which X signifies cycloalkyl 
substituted by ethylenedioxy, or 
f) hydrogenating a compound of formula I in which X signifies a cycloalkyl or 
piperidinyl residue substituted by -O-(CH
2
)
2
-CN, =CH-CN or -CH
2
CN to the 
amino compound, or 
g) in the case of a compound of formula I in which X signifies a cycloalkyl or 
piperidinyl residue substituted by an oxo group, 


converting this into a hydroxyimino group, or 
reducing this to a hydroxy group, or 
converting this with appropriately substituted amines into a - 
NH(CH
2
)
n
NHCOC
6
H
4
R
3
 group, wherein R
3
 and n have the above significances, 
converting this into a methylene group, a benzylidene group, a 
dimethylmethylene group, a methylene-nitrilo group or into a 

methoxycarbonylmethylene group, or 
converting this into an ethylenedioxy group, or 
converting this into an amino group, or 
converting this with a corresponding phosphonate into a =CH-CN group, or 
h) in the case of a compound of formula I in which X signifies a cycloalkyl or 
piperidinyl residue substituted by a hydroxy group, 


converting this with acrylonitrile into a -O(CH
2
)
2
CN group, or 
alkylating or acylating this with corresponding alkyl, aryl or acyl halides, or 
halogenating this with suitable halogenating agents, or 
reacting this to give the corresponding sulphanyl compounds and, if desired, 
subsequently oxidizing these to the sulphinyl or sulphonyl compounds, or 
i) in the case of a compound of formula I in which X signifies a cycloalkyl 
residue substituted by a hydroxy group, 


dehydrogenating this to a cycloalkenyl residue, or 
j) in the case of a compound of formula I in which X signifies 
a cycloalkyl or piperidinyl residue substituted by a 

-O(CH
2
)
n
-SOCH
3
- group, 

converting this into a -O(CH
2
)
n
CN- group, or 
k) in the case of a compound of formula I in which X signifies a cycloalkyl 
residue, a piperidinyl residue or a protected piperidinyl residue, which is not linked 

via a nitrogen, 

acylating this with corresponding acylating agents, or 
l) in the case of a compound of formula I in which X signifies a cycloalkyl or 
piperidinyl residue substituted by a methylene group, 


converting this into a hydroxymethyl group, or 
converting this into a 4-hydroxy-4-methyl group, and 
m) if desired, converting a basic compound of formula I into a pharmaceutically 
usable salt by means of an acid. 
A medicament containing a compound according to any one of claims 
1 to 20 and a therapeutically inert excipient. 
A medicament for the control or prevention of panic and anxiety 
states, cognitive disorders and neurodegenerative diseases such as Parkinson's disease 

and Alzheimer's disease, containing a compound according to any one of claims 1-20 

and a therapeutically inert excipient. 
The use of compounds according to any one of claims 1 to 11 for the 
production of medicaments for the control or prevention of panic and anxiety states, 

cognitive disorders and neurodegenerative diseases such as Parkinson's disease and 
Alzheimer's disease. 
</CLAIMS>
</TEXT>
</DOC>
